Systemic Sclerosis
TAK1 regulates fibroinflammatory signaling central to SSc
Systemic Sclerosis
Discovery of TAK1 as a novel drug target for SSc
Transforming growth factor-β-activated kinase 1 (TAK1) has emerged as a significant player in the pathogenesis of systemic sclerosis (SSc), a chronic autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation. TAK1 is a key mediator in various signaling pathways, including the transforming growth factor-β (TGF-β) pathway, which is central to the development of fibrosis in SSc. Our research indicates that TAK1 is involved in the activation of fibroblasts and the excessive production of extracellular matrix components, both hallmarks of SSc. Inhibition of TAK1 has been shown to reduce fibrosis in preclinical models, suggesting its potential as a therapeutic target. Studies have demonstrated that targeting TAK1 can mitigate the activation of profibrotic pathways and decrease the expression of fibrosis-related genes. These findings highlight TAK1 as a novel and promising target for therapeutic intervention in systemic sclerosis, offering a new avenue for the development of treatments aimed at halting or reversing the fibrotic processes in this debilitating disease.
Current Treatments for SSc
TAK1 inhibition with HS-276 significantly reduced fibrosis in clinical samples
Benefits of Our
Application
Orally bioavailable lead TAK1 inhibitor with novel MOA in SSc
Targeting the fibroinflammatory axis central to several underlying aspects of SSc etiology.
Potential to address critical patient needs currently not addressed in approved therapeutics.
Additional information and resources
Our Technology
First selective orally bioavailable inhibitors of TAK1 for the treatment of RA
Our Company
EydisBio is a small biotech located in Durham, North Carolina. Originally created as a spinout of Duke University, EydisBio has gone on to become a leader for the development of selective and potent small molecule inhibitors of disease relevant kinases.
Our Team
Our team is composed of experienced pharmacologists, chemists, and biologists who leverage their years of industry experience to advance small molecule inhibitors into clinics.
"*" indicates required fields